Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy.

Bokhovchuk F, Mesrouze Y, Izaac A, Meyerhofer M, Zimmermann C, Fontana P, Schmelzle T, Erdmann D, Furet P, Kallen J, Chène P.

FEBS J. 2019 Mar 23. doi: 10.1111/febs.14817. [Epub ahead of print]

PMID:
30903741
2.

Adaptation of the bound intrinsically disordered protein YAP to mutations at the YAP:TEAD interface.

Mesrouze Y, Bokhovchuk F, Izaac A, Meyerhofer M, Zimmermann C, Fontana P, Schmelzle T, Erdmann D, Furet P, Kallen J, Chène P.

Protein Sci. 2018 Oct;27(10):1810-1820. doi: 10.1002/pro.3493.

PMID:
30058229
3.

Correction of copy number induced false positives in CRISPR screens.

de Weck A, Golji J, Jones MD, Korn JM, Billy E, McDonald ER 3rd, Schmelzle T, Bitter H, Kauffmann A.

PLoS Comput Biol. 2018 Jul 19;14(7):e1006279. doi: 10.1371/journal.pcbi.1006279. eCollection 2018 Jul.

4.

Size Variation under Domestication: Conservatism in the inner ear shape of wolves, dogs and dingoes.

Schweizer AV, Lebrun R, Wilson LAB, Costeur L, Schmelzle T, Sánchez-Villagra MR.

Sci Rep. 2017 Oct 17;7(1):13330. doi: 10.1038/s41598-017-13523-9.

5.

Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.

Mesrouze Y, Meyerhofer M, Bokhovchuk F, Fontana P, Zimmermann C, Martin T, Delaunay C, Izaac A, Kallen J, Schmelzle T, Erdmann D, Chène P.

Protein Sci. 2017 Dec;26(12):2399-2409. doi: 10.1002/pro.3312. Epub 2017 Nov 11.

6.

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening.

McDonald ER 3rd, de Weck A, Schlabach MR, Billy E, Mavrakis KJ, Hoffman GR, Belur D, Castelletti D, Frias E, Gampa K, Golji J, Kao I, Li L, Megel P, Perkins TA, Ramadan N, Ruddy DA, Silver SJ, Sovath S, Stump M, Weber O, Widmer R, Yu J, Yu K, Yue Y, Abramowski D, Ackley E, Barrett R, Berger J, Bernard JL, Billig R, Brachmann SM, Buxton F, Caothien R, Caushi JX, Chung FS, Cortés-Cros M, deBeaumont RS, Delaunay C, Desplat A, Duong W, Dwoske DA, Eldridge RS, Farsidjani A, Feng F, Feng J, Flemming D, Forrester W, Galli GG, Gao Z, Gauter F, Gibaja V, Haas K, Hattenberger M, Hood T, Hurov KE, Jagani Z, Jenal M, Johnson JA, Jones MD, Kapoor A, Korn J, Liu J, Liu Q, Liu S, Liu Y, Loo AT, Macchi KJ, Martin T, McAllister G, Meyer A, Mollé S, Pagliarini RA, Phadke T, Repko B, Schouwey T, Shanahan F, Shen Q, Stamm C, Stephan C, Stucke VM, Tiedt R, Varadarajan M, Venkatesan K, Vitari AC, Wallroth M, Weiler J, Zhang J, Mickanin C, Myer VE, Porter JA, Lai A, Bitter H, Lees E, Keen N, Kauffmann A, Stegmeier F, Hofmann F, Schmelzle T, Sellers WR.

Cell. 2017 Jul 27;170(3):577-592.e10. doi: 10.1016/j.cell.2017.07.005.

7.

Dissection of the interaction between the intrinsically disordered YAP protein and the transcription factor TEAD.

Mesrouze Y, Bokhovchuk F, Meyerhofer M, Fontana P, Zimmermann C, Martin T, Delaunay C, Erdmann D, Schmelzle T, Chène P.

Elife. 2017 Apr 21;6. pii: e25068. doi: 10.7554/eLife.25068.

8.

CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions.

Munoz DM, Cassiani PJ, Li L, Billy E, Korn JM, Jones MD, Golji J, Ruddy DA, Yu K, McAllister G, DeWeck A, Abramowski D, Wan J, Shirley MD, Neshat SY, Rakiec D, de Beaumont R, Weber O, Kauffmann A, McDonald ER 3rd, Keen N, Hofmann F, Sellers WR, Schmelzle T, Stegmeier F, Schlabach MR.

Cancer Discov. 2016 Aug;6(8):900-13. doi: 10.1158/2159-8290.CD-16-0178. Epub 2016 Jun 3.

9.

Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.

Mavrakis KJ, McDonald ER 3rd, Schlabach MR, Billy E, Hoffman GR, deWeck A, Ruddy DA, Venkatesan K, Yu J, McAllister G, Stump M, deBeaumont R, Ho S, Yue Y, Liu Y, Yan-Neale Y, Yang G, Lin F, Yin H, Gao H, Kipp DR, Zhao S, McNamara JT, Sprague ER, Zheng B, Lin Y, Cho YS, Gu J, Crawford K, Ciccone D, Vitari AC, Lai A, Capka V, Hurov K, Porter JA, Tallarico J, Mickanin C, Lees E, Pagliarini R, Keen N, Schmelzle T, Hofmann F, Stegmeier F, Sellers WR.

Science. 2016 Mar 11;351(6278):1208-13. doi: 10.1126/science.aad5944. Epub 2016 Feb 11.

10.

YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers.

Stein C, Bardet AF, Roma G, Bergling S, Clay I, Ruchti A, Agarinis C, Schmelzle T, Bouwmeester T, Schübeler D, Bauer A.

PLoS Genet. 2015 Aug 21;11(8):e1005465. doi: 10.1371/journal.pgen.1005465. eCollection 2015 Aug.

11.

YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors.

Marti P, Stein C, Blumer T, Abraham Y, Dill MT, Pikiolek M, Orsini V, Jurisic G, Megel P, Makowska Z, Agarinis C, Tornillo L, Bouwmeester T, Ruffner H, Bauer A, Parker CN, Schmelzle T, Terracciano LM, Heim MH, Tchorz JS.

Hepatology. 2015 Nov;62(5):1497-510. doi: 10.1002/hep.27992. Epub 2015 Aug 25.

PMID:
26173433
12.

The surprising features of the TEAD4-Vgll1 protein-protein interaction.

Mesrouze Y, Hau JC, Erdmann D, Zimmermann C, Fontana P, Schmelzle T, Chène P.

Chembiochem. 2014 Mar 3;15(4):537-42. doi: 10.1002/cbic.201300715. Epub 2014 Feb 6.

PMID:
24504694
13.

The TEAD4-YAP/TAZ protein-protein interaction: expected similarities and unexpected differences.

Hau JC, Erdmann D, Mesrouze Y, Furet P, Fontana P, Zimmermann C, Schmelzle T, Hofmann F, Chène P.

Chembiochem. 2013 Jul 8;14(10):1218-25. doi: 10.1002/cbic.201300163. Epub 2013 Jun 18.

PMID:
23780915
14.

The tyrosine phosphatase PTPN14 is a negative regulator of YAP activity.

Michaloglou C, Lehmann W, Martin T, Delaunay C, Hueber A, Barys L, Niu H, Billy E, Wartmann M, Ito M, Wilson CJ, Digan ME, Bauer A, Voshol H, Christofori G, Sellers WR, Hofmann F, Schmelzle T.

PLoS One. 2013 Apr 16;8(4):e61916. doi: 10.1371/journal.pone.0061916. Print 2013.

15.

The path to oncology drug target validation: an industry perspective.

Cortés-Cros M, Schmelzle T, Stucke VM, Hofmann F.

Methods Mol Biol. 2013;986:3-13. doi: 10.1007/978-1-62703-311-4_1.

PMID:
23436402
16.

K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.

Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V, Schmelzle T, Lai A, Brachmann SM, Bentires-Alj M, Roberts TM, Sellers WR, Hofmann F, Maira SM.

PLoS One. 2012;7(8):e44146. doi: 10.1371/journal.pone.0044146. Epub 2012 Aug 31.

17.

Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2.

Worster DT, Schmelzle T, Solimini NL, Lightcap ES, Millard B, Mills GB, Brugge JS, Albeck JG.

Sci Signal. 2012 Mar 6;5(214):ra19. doi: 10.1126/scisignal.2001986.

18.

Engineering tumors with 3D scaffolds.

Fischbach C, Chen R, Matsumoto T, Schmelzle T, Brugge JS, Polverini PJ, Mooney DJ.

Nat Methods. 2007 Oct;4(10):855-60. Epub 2007 Sep 2.

PMID:
17767164
19.

Exceptionally preserved North American Paleogene metatherians: adaptations and discovery of a major gap in the opossum fossil record.

Sánchez-Villagra M, Ladevèze S, Horovitz I, Argot C, Hooker JJ, Macrini TE, Martin T, Moore-Fay S, de Muizon C, Schmelzle T, Asher RJ.

Biol Lett. 2007 Jun 22;3(3):318-22.

20.

Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis.

Schmelzle T, Mailleux AA, Overholtzer M, Carroll JS, Solimini NL, Lightcap ES, Veiby OP, Brugge JS.

Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3787-92. Epub 2007 Feb 26.

21.

BIM regulates apoptosis during mammary ductal morphogenesis, and its absence reveals alternative cell death mechanisms.

Mailleux AA, Overholtzer M, Schmelzle T, Bouillet P, Strasser A, Brugge JS.

Dev Cell. 2007 Feb;12(2):221-34.

22.

Activation of the RAS/cyclic AMP pathway suppresses a TOR deficiency in yeast.

Schmelzle T, Beck T, Martin DE, Hall MN.

Mol Cell Biol. 2004 Jan;24(1):338-51.

23.

Quantitation of changes in protein phosphorylation: a simple method based on stable isotope labeling and mass spectrometry.

Bonenfant D, Schmelzle T, Jacinto E, Crespo JL, Mini T, Hall MN, Jenoe P.

Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):880-5. Epub 2003 Jan 22.

24.

The RHO1-GAPs SAC7, BEM2 and BAG7 control distinct RHO1 functions in Saccharomyces cerevisiae.

Schmidt A, Schmelzle T, Hall MN.

Mol Microbiol. 2002 Sep;45(5):1433-41.

25.
26.

TIP41 interacts with TAP42 and negatively regulates the TOR signaling pathway.

Jacinto E, Guo B, Arndt KT, Schmelzle T, Hall MN.

Mol Cell. 2001 Nov;8(5):1017-26.

27.

Sphingoid base signaling via Pkh kinases is required for endocytosis in yeast.

Friant S, Lombardi R, Schmelzle T, Hall MN, Riezman H.

EMBO J. 2001 Dec 3;20(23):6783-92.

28.

TOR, a central controller of cell growth.

Schmelzle T, Hall MN.

Cell. 2000 Oct 13;103(2):253-62. Review.

29.

Eap1p, a novel eukaryotic translation initiation factor 4E-associated protein in Saccharomyces cerevisiae.

Cosentino GP, Schmelzle T, Haghighat A, Helliwell SB, Hall MN, Sonenberg N.

Mol Cell Biol. 2000 Jul;20(13):4604-13.

30.

PDK1 homologs activate the Pkc1-mitogen-activated protein kinase pathway in yeast.

Inagaki M, Schmelzle T, Yamaguchi K, Irie K, Hall MN, Matsumoto K.

Mol Cell Biol. 1999 Dec;19(12):8344-52.

31.

[Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine].

Meissner A, Schmelzle T, Simon R.

Z Kardiol. 1996 Nov;85(11):839-46. German.

PMID:
9064946

Supplemental Content

Loading ...
Support Center